Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

136 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Monoclonal antibody therapy for solid tumors.
Green MC, Murray JL, Hortobagyi GN. Green MC, et al. Cancer Treat Rev. 2000 Aug;26(4):269-86. doi: 10.1053/ctrv.2000.0176. Cancer Treat Rev. 2000. PMID: 10913382 Review.
Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.
Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F. Gonzalez-Angulo AM, et al. Among authors: green mc. Clin Breast Cancer. 2015 Oct;15(5):325-31. doi: 10.1016/j.clbc.2015.03.004. Epub 2015 Mar 24. Clin Breast Cancer. 2015. PMID: 25913905 Free PMC article. Clinical Trial.
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Peintinger F, et al. Among authors: green mc. Ann Oncol. 2008 Dec;19(12):2020-5. doi: 10.1093/annonc/mdn427. Epub 2008 Jul 29. Ann Oncol. 2008. PMID: 18667396 Free PMC article.
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.
Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Cristofanilli M, et al. Among authors: green mc. Ann Oncol. 2008 Oct;19(10):1713-9. doi: 10.1093/annonc/mdn352. Epub 2008 May 29. Ann Oncol. 2008. PMID: 18515258 Free PMC article. Clinical Trial.
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.
Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI. Holden SN, et al. Among authors: green m. Ann Oncol. 2005 Aug;16(8):1391-7. doi: 10.1093/annonc/mdi247. Epub 2005 May 19. Ann Oncol. 2005. PMID: 15905307 Clinical Trial.
Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.
Loehrer PJ Sr, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR Jr, Livingston R, Johnson DH. Loehrer PJ Sr, et al. Among authors: green m. Cancer. 2001 Jun 1;91(11):2010-5. Cancer. 2001. PMID: 11391579 Clinical Trial.
Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients.
Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Cheng YC, et al. Among authors: green mc. Br J Cancer. 2010 Oct 26;103(9):1331-4. doi: 10.1038/sj.bjc.6605918. Epub 2010 Sep 28. Br J Cancer. 2010. PMID: 20877352 Free PMC article. Clinical Trial.
The role of anthracyclines in the treatment of gastric cancer.
Wadler S, Green M, Muggia F. Wadler S, et al. Among authors: green m. Cancer Treat Rev. 1985 Jun;12(2):105-32. doi: 10.1016/0305-7372(85)90003-9. Cancer Treat Rev. 1985. PMID: 3902215 Review.
A phase II study of carboplatin and CHIP in patients with metastatic colon carcinoma.
Asbury RF, Kramer A, Green M, Qazi R, Skeel RT, Haller DG. Asbury RF, et al. Among authors: green m. Am J Clin Oncol. 1989 Oct;12(5):416-9. doi: 10.1097/00000421-198910000-00011. Am J Clin Oncol. 1989. PMID: 2679039 Clinical Trial.
136 results
Jump to page